Showing results (11-20 of 45) with videos related to
Sort By:
Pageof 5
Journal of the American College of Surgeons|December 4, 2023
Axillary Nodal Response to Neoadjuvant T-DM1 Combined with Pertuzumab in a Prospective Phase II Multi-Institution Clinical TrialAnna Weiss, Qingchun Jin, Adrienne G Waks, et al.Frontiers in Immunology|June 17, 2021
The Immunology of Hormone Receptor Positive Breast CancerJonathan Goldberg, Ricardo G Pastorello, Tuulia Vallius, et al.NPJ Breast Cancer|April 4, 2024
Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancerPaolo Tarantino, Julieta Leone, Carlos T Vallejo, et al.Breast Cancer Research and Treatment|August 12, 2025
Combined intermittent fasting and exercise intervention in patients with metastatic, hormone receptor-positive breast cancer (FastER): a pilot studyPaola Gonzalo-Encabo, Anita Giobbie-Hurder, Dorothy D Sears, et al.Cancer Treatment Reviews|November 21, 2024
Estrogen Signaling in Early-Stage Breast Cancer: Impact on Neoadjuvant Chemotherapy and ImmunotherapyChiara Corti, Busem Binboğa Kurt, Beyza Koca, et al.Journal of the National Cancer Institute|August 14, 2025
Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancerPaolo Tarantino, Do Lee, Julia Foldi, et al.Cancer|March 23, 2023
Nodal positivity and systemic therapy among patients with clinical T1-T2N0 human epidermal growth factor receptor-positive breast cancer: Results from two international cohortsAnna Weiss, Olga Martínez-Sáez, Adrienne G Waks, et al.Journal for Immunotherapy of Cancer|October 17, 2022
Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancerAdrienne G Waks, Tanya E Keenan, Tianyu Li, et al.Cancer|August 30, 2024
Generative artificial intelligence as a source of breast cancer information for patients: Proceed with cautionKo Un Park, Stuart Lipsitz, Laura S Dominici, et al.Nature Genetics|December 12, 2018
Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapiesUtthara Nayar, Ofir Cohen, Christian Kapstad, et al.Pageof 5